Preliminary trials indicate that the compound – a dual activator of gut hormone and a related hormone receptors – may provide a considerable improvement in metabolic loss therapies. Unlike existing treatments , this dual-action compound appears to modify hunger and energy utilization through multiple pathways . Although additional investigation